Biochemical Society Transactions

Journal Article

Commercialization of cellular immunotherapies for cancer

Walker, Anthony; Johnson, Robert

2016 Biochemical Society Transactions

doi:10.1042/BST20150240 pmid:27068936

Successful commercialization of a cell therapy requires more than proving safety and efficacy to the regulators. The inherent complexity of cellular products delivers particular manufacturing, logistical and reimbursement hurdles that threaten commercial viability for any therapy with a less than...

Download Only

Journal Article

Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer

Achkova, Daniela; Maher, John

2016 Biochemical Society Transactions

doi:10.1042/BST20150245 pmid:27068937

Cancer cells employ a variety of mechanisms to evade apoptosis and senescence. Pre-eminent among these is the aberrant co-expression of growth factors and their ligands, forming an autocrine growth loop that promotes tumour formation and progression. One growth loop whose transforming potential...

Download Only

Journal Article

Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?

Boardman, Dominic; Maher, John; Lechler, Robert; Smyth, Lesley; Lombardi, Giovanna

2016 Biochemical Society Transactions

doi:10.1042/BST20150247 pmid:27068938

Adoptive regulatory T-cell (Treg) therapy using autologous Tregs expanded ex vivo is a promising therapeutic approach which is currently being investigated clinically as a means of treating various autoimmune diseases and transplant rejection. Despite this, early results have highlighted the need...

Download Only

Journal Article

The integrin αvβ6: a novel target for CAR T-cell immunotherapy?

Whilding, Lynsey M.; Vallath, Sabari; Maher, John

2016 Biochemical Society Transactions

doi:10.1042/BST20150249 pmid:27068939

Immunotherapy of cancer using chimeric antigen receptor (CAR) T-cells is a rapidly expanding field. CARs are fusion molecules that couple the binding of a tumour-associated cell surface target to the delivery of a tailored T-cell activating signal. Re-infusion of such genetically engineered...

Download Only

Journal Article

SHP-1: the next checkpoint target for cancer immunotherapy?

Watson, H. Angharad; Wehenkel, Sophie; Matthews, James; Ager, Ann

2016 Biochemical Society Transactions

doi:10.1042/BST20150251 pmid:27068940

The immense power of the immune system is harnessed in healthy individuals by a range of negative regulatory signals and checkpoints. Manipulating these checkpoints through inhibition has resulted in striking immune-mediated clearance of otherwise untreatable tumours and metastases;...

Download Only

Journal Article

The role of the HGF/Met axis in mesothelioma

Thayaparan, Thivyan; Spicer, James F.; Maher, John

2016 Biochemical Society Transactions

doi:10.1042/BST20150252 pmid:27068941

Malignant mesothelioma is an asbestos-related cancer that occurs most commonly in the pleural space and is incurable. Increasing evidence suggests that aberrant receptor tyrosine kinase (RTK)-directed signalling plays a key role in the pathogenesis of this cancer. In the majority of...

Download Only

Journal Article

Approaches to augment CAR T-cell therapy by targeting the apoptotic machinery

Karlsson, Hannah

2016 Biochemical Society Transactions

doi:10.1042/BST20150253 pmid:27068942

Chimaeric antigen receptor (CAR) T-cells have shown impressive results in patients with B-cell leukaemia. Yet, in patients with lymphoma durable responses are still rare and heavy preconditioning required. Apoptosis resistance is considered a hallmark of cancer, often conveyed by a halted...

Download Only

Journal Article

Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells

Ager, Ann; Watson, H. Angharad; Wehenkel, Sophie C.; Mohammed, Rebar N.

2016 Biochemical Society Transactions

doi:10.1042/BST20150254 pmid:27068943

The success of adoptive T-cell therapies for the treatment of cancer patients depends on transferred T-lymphocytes finding and infiltrating cancerous tissues. For intravenously transferred T-cells, this means leaving the bloodstream (extravasation) from tumour blood vessels. In inflamed tissues,...

Download Only

Journal Article

Dynamic imaging for CAR-T-cell therapy

Emami-Shahri, Nia; Papa, Sophie

2016 Biochemical Society Transactions

doi:10.1042/BST20150257 pmid:27068944

Chimaeric antigen receptor (CAR) therapy is entering the mainstream for the treatment of CD19 + cancers. As is does we learn more about resistance to therapy and the role, risks and management of toxicity. In solid tumour CAR therapy research the route to the clinic is less smooth with a wealth...

Download Only

Journal Article

Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells

Navai, Shoba A.; Ahmed, Nabil

2016 Biochemical Society Transactions

doi:10.1042/BST20150266 pmid:27068945

A variety of distinct and redundant mechanisms support tumour propagation and survival. Tumour parenchyma consists of a variety of geographically diverse cells with varying genetic expression among subclonal populations. Additionally, the solid tumour microenvironment consists of a dense network...

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Biochemical Society Transactions

Related Journals:

Advanced Search

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Biochemical Society Transactions

Related Journals:

Our policy towards the use of cookies